Zimbabwe has turned down a substantial US health deal valued at 367 million US dollars (£272m) over five years due to Washington's insistence on sensitive data.
The decision became public following a government memo dated December was disclosed, indicating that President Emmerson Mnangagwa believed the agreement was "unbalanced".
An official representative has since clarified that the United States was requesting health data for scientific study and commercial purposes while was unwilling to share the benefits from any future vaccines.
"We will now turn to the challenging and unfortunate task of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had furnished more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for more negotiations to find a deal agreeable to all parties so the country's vital HIV programme can be sustained.
Wider Context
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a high court blocked a similar deal with the US after concerns were filed about the security of Kenyans' medical information.
Since resuming office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump argued its expenditure was "inefficient" and his government was seeking government-to-government agreements to boost transparency and accountability.
As per statements, Sixteen African countries have to date signed similar health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration could have provided immense benefits for Zimbabwean communities, especially the 1.2 million currently on HIV treatment through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no equivalent guarantee of benefiting from any medical innovations – such as new medicines or tests – that could be developed from that shared data," he stated.
"In essence, our nation would provide the basic resources for medical research without any assurance that the resulting innovations would be accessible to our citizens if a future disease outbreak emerge."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were disrupting systems previously set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing system designed to manage potential global health emergencies.
"This system is intended to ensure that when a nation provides its samples, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We encourage further discussions with our American counterparts on how subsequent collaboration could be arranged in a way that respects the sovereignty and interests of both nations."
Medical Community Response
A leading public health body said it understood the official position, but urged that negotiations need to persist considering a large portion of the country's HIV programmes relied on foreign aid.
"Where technical issues arise, including those involving information security or agreement terms, these can often be resolved through detailed discussion and mutually agreed protections," it commented.
The situation emphasises the complex tensions between accepting crucial international aid and protecting local interests in an ever more data-driven world.